Andersen, P., Doherty T.M. (2005) The success and failure of BCG – implications for a
novel TB vaccine. Nature Reviews Microbiology 3: 656-662.
Andersen, P. (2007). Vaccine strategies against latent tuberculosis infection. Trends in Microbiology 15(1): 7-13.
Arnold, K., Bordoli, L., Kopp, J., Schwede, T. (2006) The SWISS-MODEL Workspace: a web-based environment for protein structure homology modeling. Bioinformatics 22(2): 195-201.
Bivas-Benita, M., Lin, M.Y., Bal, S.M., van Meijgaarden, K.E., Franken, K.L., Friggen, A.H., Junginger, H.E., Borchard, G., Klein, M.R., Ottenhoff, T.H. (2009) Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27(30): 4010-4017.
Colditz, G.A., Brewer, T.F., Berkey, C.S., Wilson, M.E., Burdick, E., Fineberg, H.V., Mosteller, F. (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Me ta-analysis of the published literature. the Journal of the American Medical
Association 271(9): 698-702.
Coppola, M., van den Eeden, S.J., Wilson, L., Franken, K.L., Ottenhoff, T.H., Geluk, A.(2015) Synthetic long peptide derived from Mycobacterium tuberculosis latency antigen Rv1733c protects against tuberculosis. Clinical and Vaccine Immunology 22(9): 1060-1069.
Fine, P.E. (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346(8986): 1339-1345.
Green, M.R., Sambrook, J. (2012) Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press New York.
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259): 680-685.
Lew, J.M., Kapopoulou, A., Jones, L.M., Cole, S.T. (2011). TubercuList-10 years after.Tuberculosis 91(1): 1-7.
Lin, M.Y., Geluk, A., Smith, S.G., Stewart, A.L., Friggen, A.H., Franken, K.L.M.C. (2007)Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. Infection and Immunity 75(7): 3523-3530.
Nguyen Thi, L.T., Sarmiento, M.E., Calero, R., Camacho, F., Reyes, F., Hossain, M.M.(2014) Immunoinformatics study on highly expressed Mycobacterium tuberculosis genes during infection. Tuberculosis 94(5): 475-81.
Ottenhoff, T.H., Kaufmann, S.H. (2012) Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathogens 8(5): e1002607.
Partnership WST. (2010) The global plan to stop TB 2011-2015: transforming the flight towards elimination of tuberculosis. Geneva: World Health Organization.http://www.who.int/iris/handle/10665/44437
WHO Global Report. (2016) World Health Organization. Global tuberculosis report 2016. WHO/HTM/TB/2016.13. Geneva: World Health Organization.
Zhang, W., Jiang, H., Bai, Y.L., Kang, J., Xu, Z.K., Wang, L.M. (2014) Construction and
immunogenicity of the DNA vaccine of Mycobacterium tuberculosis dormancy antigen Rv1733c. Scandinavian Journal of Immunology 79(5): 292-298.
Zvi, A., Ariel, N., Fulkerson, J., Sadoff, J.C., Shafferman A. (2008) Whole genome identification of Mycobacterium tuberculosis vaccine candidates by comprehensive data mining and bioinformatic analyses. BMC Medical Genomics 1: 18.